

Fatih Arslan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/765132/publications.pdf>

Version: 2024-02-01

55
papers

7,430
citations

201385
27
h-index

182168
51
g-index

58
all docs

58
docs citations

58
times ranked

11291
citing authors

#	ARTICLE	IF	CITATIONS
1	Multiple culprit lesions in ST-segment elevation myocardial infarction with cardiogenic shock: a case of simultaneous thrombosis of two infarct-related arteries. Netherlands Heart Journal, 2022, , 1.	0.3	0
2	Actual management costs of patients with non-valvular atrial fibrillation treated with percutaneous left atrial appendage closure or oral anticoagulation. International Journal of Cardiology, 2022, 351, 61-64.	0.8	0
3	Sex differences in treatment strategy for coronary artery aneurysms: Insights from the international Coronary Artery Aneurysm Registry. Netherlands Heart Journal, 2022, 30, 328-334.	0.3	1
4	Reverse remodeling after percutaneous transluminal septal myocardial ablation in severe but asymptomatic LVOT obstruction (RASTA) study: Rationale and design of transcatheter septal reduction in asymptomatic patients with severe hypertrophic obstructive cardiomyopathy. Catheterization and Cardiovascular Interventions, 2021, 97, 488-492.	0.7	0
5	Virtual support for remote proctoring in TAVR during COVID-19. Catheterization and Cardiovascular Interventions, 2021, 98, E733-E736.	0.7	14
6	2020 ESC Guidelines on acute coronary syndrome without ST-segment elevation. Netherlands Heart Journal, 2021, 29, 557-565.	0.3	9
7	Left atrial appendage closure with the watchman device reduces atrial fibrillation management costs. Clinical Research in Cardiology, 2021, 111, 105.	1.5	5
8	Ventricular TLR4 Levels Abrogate TLR2-Mediated Adverse Cardiac Remodeling upon Pressure Overload in Mice. International Journal of Molecular Sciences, 2021, 22, 11823.	1.8	6
9	Percutaneous coronary intervention for chronic total coronary occlusion: Do. Or do not. There is no try. Netherlands Heart Journal, 2021, 29, 1-3.	0.3	1
10	Coronary artery aneurysms, insights from the international coronary artery aneurysm registry (CAAR). International Journal of Cardiology, 2020, 299, 49-55.	0.8	46
11	Indications for an early invasive strategy in NSTEMI-ACS patients. Netherlands Heart Journal, 2020, 28, 131-135.	0.3	6
12	Guidelines for the management of myocardial infarction/injury with non-obstructive coronary arteries (MINOCA): a position paper from the Dutch ACS working group. Netherlands Heart Journal, 2020, 28, 116-130.	0.3	42
13	Statins Promote Cardiac Infarct Healing by Modulating Endothelial Barrier Function Revealed by Contrast-Enhanced Magnetic Resonance Imaging. Arteriosclerosis, Thrombosis, and Vascular Biology, 2018, 38, 186-194.	1.1	20
14	2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: comments from the Dutch ACS working group. Netherlands Heart Journal, 2018, 26, 417-421.	0.3	48
15	The selective NLRP3-inflammasome inhibitor MCC950 reduces infarct size and preserves cardiac function in a pig model of myocardial infarction. European Heart Journal, 2017, 38, ehv247.	1.0	222
16	Guidance of interventions in structural heart disease; three-dimensional techniques are here to stay. Netherlands Heart Journal, 2017, 25, 63-64.	0.3	3
17	Right ventricular dysfunction in left-sided heart failure with preserved versus reduced ejection fraction. European Journal of Heart Failure, 2017, 19, 1664-1671.	2.9	224
18	Risk stratification of Asian patients with heart failure and reduced ejection fraction: the effectiveness of the Echo Heart Failure Score. European Journal of Heart Failure, 2017, 19, 1732-1735.	2.9	6

#	ARTICLE	IF	CITATIONS
19	Leukocytic Toll-Like Receptor 2 Deficiency Preserves Cardiac Function And Reduces Fibrosis In Sustained Pressure Overload. Scientific Reports, 2017, 7, 9193.	1.6	23
20	The management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: early invasive strategy for all?. Netherlands Heart Journal, 2017, 25, 170-172.	0.3	4
21	Leukocyte-Associated Immunoglobulin-like Receptor-1 is regulated in human myocardial infarction but its absence does not affect infarct size in mice. Scientific Reports, 2017, 7, 18039.	1.6	8
22	Haptoglobin polymorphism in relation to coronary plaque characteristics on radiofrequency intravascular ultrasound and near-infrared spectroscopy in patients with coronary artery disease. International Journal of Cardiology, 2016, 221, 682-687.	0.8	1
23	Targeting danger-associated molecular patterns after myocardial infarction. Expert Opinion on Therapeutic Targets, 2016, 20, 223-239.	1.5	48
24	Assessment of Myocardial Fibrosis in Mice Using a T2*-Weighted 3D Radial Magnetic Resonance Imaging Sequence. PLoS ONE, 2015, 10, e0129899.	1.1	19
25	Acute pontine infarction after percutaneous coronary intervention: a very rare but devastating complication. Netherlands Heart Journal, 2015, 23, 366-367.	0.3	1
26	Danger Signals in Cardiovascular Disease. Mediators of Inflammation, 2014, 2014, 1-2.	1.4	7
27	Contrast-Enhanced T1-Mapping MRI for the Assessment of Myocardial Fibrosis. Current Cardiovascular Imaging Reports, 2014, 7, 1.	0.4	5
28	Quantitative T ₂ mapping of the mouse heart by segmented MLEV phase-cycled T ₂ preparation. Magnetic Resonance in Medicine, 2014, 72, 409-417.	1.9	30
29	Prognostic Value of Fractional Flow Reserve. Journal of the American College of Cardiology, 2014, 64, 1641-1654.	1.2	513
30	Highlights of Keystone symposium "Fibrosis: from bench to bedside". Fibrogenesis and Tissue Repair, 2014, 7, .	3.4	0
31	Mediators of inflammation after cardiac ischemia: The role of invariant natural killer T (iNKT) cells. Journal of Molecular and Cellular Cardiology, 2013, 63, 118-121.	0.9	0
32	Lack of haptoglobin results in unbalanced VEGF±/angiopoietin-1 expression, intramural hemorrhage and impaired wound healing after myocardial infarction. Journal of Molecular and Cellular Cardiology, 2013, 56, 116-128.	0.9	15
33	²³ Na chemical shift imaging and Gd enhancement of myocardial edema. International Journal of Cardiovascular Imaging, 2013, 29, 343-354.	0.7	11
34	Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury. Stem Cell Research, 2013, 10, 301-312.	0.3	932
35	Danger Signals in the Initiation of the Inflammatory Response after Myocardial Infarction. Mediators of Inflammation, 2013, 2013, 1-13.	1.4	101
36	Intracoronary Infusion of Allogeneic Mesenchymal Precursor Cells Directly After Experimental Acute Myocardial Infarction Reduces Infarct Size, Abrogates Adverse Remodeling, and Improves Cardiac Function. Circulation Research, 2013, 113, 153-166.	2.0	92

#	ARTICLE	IF	CITATIONS
37	Treatment With OPN-305, a Humanized Anti-“Toll-Like Receptor-2 Antibody, Reduces Myocardial Ischemia/Reperfusion Injury in Pigs. Circulation: Cardiovascular Interventions, 2012, 5, 279-287.	1.4	95
38	The innate immune response in reperfused myocardium. Cardiovascular Research, 2012, 94, 276-283.	1.8	224
39	Quantitative T 2 * assessment of acute and chronic myocardial ischemia/reperfusion injury in mice. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2012, 25, 369-379.	1.1	18
40	Metabolic Adaptation to a Disruption in Oxygen Supply during Myocardial Ischemia and Reperfusion Is Underpinned by Temporal and Quantitative Changes in the Cardiac Proteome. Journal of Proteome Research, 2012, 11, 2331-2346.	1.8	46
41	Inhibition of RIP1-dependent necrosis prevents adverse cardiac remodeling after myocardial ischemia-“reperfusion in vivo. Basic Research in Cardiology, 2012, 107, 270.	2.5	277
42	Innate immune signaling in cardiac ischemia. Nature Reviews Cardiology, 2011, 8, 292-300.	6.1	278
43	Human mesenchymal stem cell-conditioned medium improves cardiac function following myocardial infarction. Stem Cell Research, 2011, 6, 206-214.	0.3	379
44	Enabling a robust scalable manufacturing process for therapeutic exosomes through oncogenic immortalization of human ESC-derived MSCs. Journal of Translational Medicine, 2011, 9, 47.	1.8	323
45	Lack of Fibronectin-EDA Promotes Survival and Prevents Adverse Remodeling and Heart Function Deterioration After Myocardial Infarction. Circulation Research, 2011, 108, 582-592.	2.0	149
46	Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Research, 2010, 4, 214-222.	0.3	1,831
47	Myocardial Ischemia/Reperfusion Injury Is Mediated by Leukocytic Toll-Like Receptor-2 and Reduced by Systemic Administration of a Novel Anti-“Toll-Like Receptor-2 Antibody. Circulation, 2010, 121, 80-90.	1.6	319
48	TLR2 and TLR4 in Ischemia Reperfusion Injury. Mediators of Inflammation, 2010, 2010, 1-8.	1.4	152
49	Derivation and characterization of human fetal MSCs: An alternative cell source for large-scale production of cardioprotective microparticles. Journal of Molecular and Cellular Cardiology, 2010, 48, 1215-1224.	0.9	137
50	Endogenous Inflammatory Molecules Engage Toll-Like Receptors in Cardiovascular Disease. Journal of Innate Immunity, 2010, 2, 307-315.	1.8	67
51	Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium. Stem Cell Research, 2008, 1, 129-137.	0.3	531
52	Unraveling Pleiotropic Effects Of Statins. Circulation Research, 2008, 103, 334-336.	2.0	33
53	Bridging Innate Immunity and Myocardial Ischemia/Reperfusion Injury: The Search for Therapeutic Targets. Current Pharmaceutical Design, 2008, 14, 1205-1216.	0.9	77
54	Myocardial blush grade: a predictor for major adverse cardiac events after primary PTCA with stent implantation for acute myocardial infarction. Acta Cardiologica, 2007, 62, 445-451.	0.3	21

#	ARTICLE	IF	CITATIONS
55	Hypertension as a predictor of adverse cardiac events in patients with borderline fractional flow reserve.. Acta Cardiologica, 2007, 62, 367-372.	0.3	0